WebDec 9, 2024 · The full extent of human phosphorylation is still an open question under active investigation through mass spectrometry (MS) approaches 3. Notably, an in-depth study of a single cell line... WebSMARCC2 is commonly referred to as BAF170 (BRG1-associated factor 170). Immunogen SWI/SNF complex subunit SMARCC2 recombinant protein epitope signature tag (PrEST) Application Anti-SMARCC2 antibody produced in rabbit, a Prestige Antibody, is developed and validated by the Human Protein Atlas (HPA) project .
SMARCC2/BAF170 (D8O9V) Rabbit mAb Cell Signaling Technology
WebMar 22, 2024 · Main. Cancer is one of the main causes of mortality worldwide and resistance to therapy is responsible for treatment failure in the majority of patients 1.EMT is a developmental process in which epithelial cancer cells lose cell–cell adhesion and acquire mesenchymal features, including increased invasiveness and motility 4.EMT in cancer … WebMay 10, 2024 · Affecting chromatin structure, SMARCC2 plays an essential role in modulating cortical neurogenesis, and controlling cortical size and thickness. Moreover, it is associated with tumor suppression, and SMARCC2 mutations have been observed with high frequency in human cancers. brother justio fax-2840 説明書
Entry - #618362 - COFFIN-SIRIS SYNDROME 8; CSS8 - OMIM
WebSMARCC2 Polyclonal Antibody detects endogenous levels of SMARCC2 protein. Target Information Cdc73 is a tumor suppressor probably involved in transcriptional and post-transcriptional control pathways. Cdc73 is part of the PAF1 complex, a five-subunit protein complex composed of Paf1, Cdc73, Leo1, Rtf1 and Ctr9. WebSMARCC2 (BAF170, CRACC2, Rsc8) protein expression summary. The protein encoded by this gene is a member of the SWI/SNF family of proteins, whose members display helicase and ATPas e activities and which are thought to regulate transcription of certain genes by altering the chromatin structure around those genes. The encoded protein is part of the … WebDec 8, 2024 · We report here two relatively severely affected patients with two different SMARCC2 variants: one has de novo pathogenic variant, c.1824_1826del, p.(Leu609del), in a suspected hotspot region through reanalysis of previously negative clinical exome data, and the other has a likely pathogenic loss-of-function variant, c.1094_1097delAGAA, p ... brother justice mn